Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

NCT05983783 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer
Hormone Sensitive Prostate Cancer
Chemotherapy Effect

Interventions

DRUG: Docetaxel
DRUG: Rezvilutamide

Sponsor

The First Affiliated Hospital with Nanjing Medical University